drugset / Trial / NCT04977271
Mood Disorders in Head and Neck Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research study is to initiate a pharmacotherapy protocol for at-risk patients with newly diagnosed head and neck cancer in order to decrease the incidence of anxiety, depression, and uncontrolled pain during cancer treatment.
Timeline
- Start
- 2024-01-05
- Primary completion
- 2024-10-01
- Completion
- 2024-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venlafaxine | Small molecule | 187.5 mg | Oral |
| Subject | Venlafaxine | Small molecule | 300 mg | Oral |